米国のインターベンションカーディオロジー・末梢血管市場：市場規模・シェア・動向分析 (製品別・用途別)、セグメント別予測 (2025年～2030年)

米国のインターベンションカーディオロジー・末梢血管市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国のインターベンションカーディオロジー・末梢血管の市場規模は2030年までに111億9,000万米ドルに達し、予測期間中にCAGR 6.0％で成長すると予測されています。

同市場は、心血管・末梢血管疾患の負担増、低侵襲手技への嗜好の高まり、デバイス技術の継続的な進歩が牽引しています。高齢者人口の増加、糖尿病と高血圧の割合の増加、支援的な償還政策がさらに市場拡大に拍車をかけています。

心血管疾患の罹患率の増加は、インターベンションカーディオロジー・末梢血管市場の持続的成長に寄与しています。幅広い患者が様々な段階で冠動脈や末梢動脈の閉塞と診断されており、タイムリーな医療介入を促しています。診断の進歩や定期的な検診によって病気の発見が改善されるにつれて、早期かつ侵襲性の低い治療経路が重視されるようになっています。

血管形成術、ステント留置術、血栓除去術などのインターベンション処置は現在、これらの疾患を効果的に管理するための中心的な手段となっています。2024年10月、CDCの報告によると、心臓病は依然として米国の主要な死因であり、2022年には70万2,880人が死亡し、これは5人に1人の死亡に相当します。冠動脈疾患（CAD）が最も多く、37万1,000人以上が死亡しました。高血圧、高コレステロール、喫煙、糖尿病、肥満、運動不足などの危険因子が主な原因であるとされました。

米国のインターベンションカーディオロジー・末梢血管市場：分析概要

• 製品別では、冠動脈ステント分野が2024年に41.5%の最大売上シェアを占めました。
• このセグメントの成長を牽引しているのは、経皮的冠動脈インターベンション（PCI）の採用拡大、薬剤溶出ステント技術の継続的な進歩、米国における低侵襲心臓血管治療を支援する有利な償還政策です。
• 用途別では、血管形成術分野が2024年に59.2%と最大の収益シェアを占めました。このセグメントの著しい成長は、アテローム性動脈硬化性心血管病の高い有病率、薬剤溶出性バルーン・ステントの使用の増加、低侵襲血行再建術の需要の高まりが主な要因です。
• 新興企業は、市場での存在感を強化するために、新製品の発売など多様な戦略を採用しています。
• 2024年2月、ビオトロニックはPCI時のガイドワイヤー処置をサポートするMicro Rxカテーテルを米国で発売しました。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 米国のインターベンションカーディオロジー・末梢血管市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 米国のインターベンションカーディオロジー・末梢血管市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国のインターベンションカーディオロジー・末梢血管市場：製品別の推定・動向分析

• 製品セグメントダッシュボード
• 米国のインターベンションカーディオロジー・末梢血管市場：製品別の変動分析
• 米国のインターベンションカーディオロジー・末梢血管の市場規模と動向分析：製品別（2018～2030年）
• インターベンションカテーテル
• マイクロカテーテル
  • マイクロカテーテル用サポート
  • デリバリーマイクロカテーテル
  • その他
• ガイドワイヤー
• 末梢ステント
  • 自己拡張型
  • バルーン拡張可能
  • 薬剤溶出ステント
• 冠動脈ステント
  • 生体吸収性ステント
  • 薬剤溶出ステント
  • ベアメタルステント
• PTCAバルーンカテーテル
• アテローム切除デバイス
• 慢性完全閉塞デバイス
• 合成外科用移植片
• 塞栓保護デバイス
• IVCフィルター
• PTAバルーンカテーテル
• 血栓除去デバイス

第5章 米国のインターベンションカーディオロジー・末梢血管市場：用途別の推定・動向分析

• アプリケーションセグメントダッシュボード
• 米国のインターベンションカーディオロジー・末梢血管市場：アプリケーション変動分析
• 米国のインターベンションカーディオロジー・末梢血管の市場規模と動向分析：用途別（2018～2030年）
• 血管形成術
• 先天性心疾患の矯正
• 血栓除去術
• 弁形成術
• 経皮的弁修復術
• その他

第6章 競合情勢

• 最近の動向と影響分析：主な市場参入企業別
• 企業/競合の分類
• ベンダー情勢
  • 主要企業のヒートマップ分析（2024年）
• 企業プロファイル
  • B. Braun SE
  • BD
  • Cardinal Health
  • Medtronic
  • Teleflex Incorporated
  • WL Gore &Associates Inc.
  • Cook
  • Boston Scientific Corporation
  • AngioDynamics
  • Abbott
  • OrbusNeich Medical Group Holdings Limited

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. interventional cardiology and peripheral market, by region, 2018 - 2030 (USD Million)
• Table 3 U.S. interventional cardiology and peripheral market, by product, 2018 - 2030 (USD Million)
• Table 4 U.S. interventional cardiology and peripheral market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. interventional cardiology and peripheral market: market outlook
• Fig. 10 U.S. interventional cardiology and peripheral competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. interventional cardiology and peripheral market driver impact
• Fig. 16 U.S. interventional cardiology and peripheral market restraint impact
• Fig. 17 U.S. interventional cardiology and peripheral market strategic initiatives analysis
• Fig. 18 U.S. interventional cardiology and peripheral market: Product movement analysis
• Fig. 19 U.S. interventional cardiology and peripheral market: Product outlook and key takeaways
• Fig. 20 Interventional catheters estimates and forecast, 2018 - 2030
• Fig. 21 Microcatheters estimates and forecast, 2018 - 2030
• Fig. 22 Support microcatheters estimates and forecast, 2018 - 2030
• Fig. 23 Delivery microcatheters estimates and forecast, 2018 - 2030
• Fig. 24 Others estimates and forecast, 2018 - 2030
• Fig. 25 Guidewires estimates and forecast, 2018 - 2030
• Fig. 26 Peripheral stents estimates and forecast, 2018 - 2030
• Fig. 27 Self-expanding estimates and forecast, 2018 - 2030
• Fig. 28 Balloon-expandable estimates and forecast, 2018 - 2030
• Fig. 29 Drug-eluting stents estimates and forecast, 2018 - 2030
• Fig. 30 Coronary stents estimates and forecast, 2018 - 2030
• Fig. 31 Bioabsorbable stents estimates and forecast, 2018 - 2030
• Fig. 32 Drug eluting stents estimates and forecast, 2018 - 2030
• Fig. 33 Bare metal stents estimates and forecast, 2018 - 2030
• Fig. 34 PTCA balloon catheters estimates and forecast, 2018 - 2030
• Fig. 35 Atherectomy devices estimates and forecast, 2018 - 2030
• Fig. 36 Chronic total occlusion devices estimates and forecast, 2018 - 2030
• Fig. 37 Synthetic surgical grafts estimates and forecast, 2018 - 2030
• Fig. 38 Embolic protection devices estimates and forecast, 2018 - 2030
• Fig. 39 IVC filters estimates and forecast, 2018 - 2030
• Fig. 40 PTA balloon catheters estimates and forecast, 2018 - 2030
• Fig. 41 Thrombectomy devices estimates and forecast, 2018 - 2030
• Fig. 42 U.S. interventional cardiology and peripheral market: Application movement analysis
• Fig. 43 U.S. interventional cardiology and peripheral market: Application outlook and key takeaways
• Fig. 44 Angioplasty estimates and forecast, 2018 - 2030
• Fig. 45 Congenital heart defect correction estimates and forecast, 2018 - 2030
• Fig. 46 Thrombectomy estimates and forecast, 2018 - 2030
• Fig. 47 Valvuloplasty estimates and forecast, 2018 - 2030
• Fig. 48 Percutaneous valve repair estimates and forecast, 2018 - 2030
• Fig. 49 Others estimates and forecast, 2018 - 2030

U.S. Interventional Cardiology and Peripheral Market Growth & Trends:

The U.S. interventional cardiology and peripheral market size is anticipated to reach USD 11.19 billion by 2030, growing at a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by the growing burden of cardiovascular & peripheral vascular diseases, rising preference for minimally invasive procedures, and continuous advancements in device technology. Increasing geriatric population, higher rates of diabetes & hypertension, and supportive reimbursement policies further fuel market expansion.

The increasing incidence of cardiovascular conditions contributes to sustained growth in the interventional cardiology and peripheral market. A wide range of patients are being diagnosed with coronary and peripheral arterial blockages at various stages, prompting timely medical intervention. As disease detection improves through diagnostic advancements and routine check-ups, there is greater emphasis on early and less invasive treatment pathways.

Interventional procedures such as angioplasty, stenting, and thrombectomy are now central to managing these conditions effectively. In October 2024, the CDC reported that heart disease remained the leading cause of death in the U.S., responsible for 702,880 deaths in 2022, equivalent to one in every five deaths. Coronary artery disease (CAD) was the most common form, killing over 371,000 people. Risk factors such as high blood pressure, high cholesterol, smoking, diabetes, obesity, and physical inactivity were identified as major contributors.

U.S. Interventional Cardiology And Peripheral Market Report Highlights:

• Based on product, the coronary stents segment accounted for the largest revenue share of 41.5% in 2024.
• The segment growth is driven by increasing adoption of Percutaneous Coronary Interventions (PCI), continuous advancements in drug-eluting stent technologies, and favorable reimbursement policies supporting minimally invasive cardiovascular procedures in the U.S.
• Based on application, the angioplasty segment accounted for the largest revenue share of 59.2% in 2024. The significant growth of this segment is largely driven by the high prevalence of atherosclerotic cardiovascular disease, increasing use of drug-eluting balloons & stents, and rising demand for minimally invasive revascularization procedures.
• Emerging players are adopting diverse strategies, such as new product launches, to strengthen their market presence.
• In February 2024, Biotronik launched the Micro Rx catheter in the U.S. to support guidewire procedures during PCI, reflecting ongoing technological progress and sustained market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Interventional Cardiology and Peripheral Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Interventional Cardiology and Peripheral Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Interventional Cardiology and Peripheral Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. U.S. Interventional Cardiology and Peripheral Market: Product Movement Analysis
• 4.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Interventional Catheters
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Microcatheters
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Support Microcatheters
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Delivery Microcatheters
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Guidewires
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Peripheral Stents
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.2. Self-Expanding
    • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.3. Balloon-Expandable
    • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.4. Drug-Eluting Stents
    • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Coronary Stents
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.2. Bioabsorbable Stents
    • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.3. Drug Eluting Stents
    • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.4. Bare Metal Stents
    • 4.8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. PTCA Balloon Catheters
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Atherectomy Devices
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Chronic Total Occlusion Devices
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.12. Synthetic Surgical Grafts
  • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.13. Embolic Protection Devices
  • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.14. IVC Filters
  • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.15. PTA Balloon Catheters
  • 4.15.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.16. Thrombectomy Devices
  • 4.16.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Interventional Cardiology and Peripheral Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. U.S. Interventional Cardiology and Peripheral Market: Application Movement Analysis
• 5.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Angioplasty
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Congenital Heart Defect Correction
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Thrombectomy
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Valvuloplasty
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Percutaneous Valve Repair
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key company heat map analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. B. Braun SE
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. BD
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Cardinal Health
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Medtronic
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Teleflex Incorporated
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. W. L. Gore & Associates Inc.
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Cook
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Boston Scientific Corporation
    • 6.4.8.1. Company overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Product benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. AngioDynamics
    • 6.4.9.1. Company overview
    • 6.4.9.2. Financial performance
    • 6.4.9.3. Product benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Abbott
    • 6.4.10.1. Company overview
    • 6.4.10.2. Financial performance
    • 6.4.10.3. Product benchmarking
    • 6.4.10.4. Strategic initiatives
  • 6.4.11. OrbusNeich Medical Group Holdings Limited
    • 6.4.11.1. Company overview
    • 6.4.11.2. Financial performance
    • 6.4.11.3. Product benchmarking
    • 6.4.11.4. Strategic initiatives